TNF and digestive system disorder: Longer treatment may offer even more pronounced advantages.44,45 The imbalance in anti-TNF use between groups at baseline may reflect the distribution of underlying disorders between groups, with subjects in the risedronate group more frequently reporting musculoskeletal and gastrointestinal disorders than subjects in the teriparatide group.